GoodRx (NASDAQ:GDRX) Announces Earnings Results

GoodRx (NASDAQ:GDRX) announced its quarterly earnings data on Wednesday. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09, FiscalAI reports. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The firm had revenue of $194.79 million during the quarter, compared to the consensus estimate of $193.27 million.

GoodRx Stock Up 3.4%

GoodRx stock traded up $0.08 during mid-day trading on Wednesday, hitting $2.45. The company had a trading volume of 2,930,644 shares, compared to its average volume of 2,913,549. GoodRx has a 12 month low of $2.10 and a 12 month high of $5.81. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s 50 day moving average price is $2.55 and its two-hundred day moving average price is $3.29. The company has a market capitalization of $831.61 million, a PE ratio of 27.22, a price-to-earnings-growth ratio of 0.86 and a beta of 1.50.

Analyst Upgrades and Downgrades

GDRX has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Barclays started coverage on shares of GoodRx in a research report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target on the stock. Bank of America reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. Finally, Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, GoodRx currently has an average rating of “Hold” and an average price target of $4.73.

Institutional Trading of GoodRx

Several institutional investors have recently bought and sold shares of the company. RPO LLC bought a new position in shares of GoodRx during the fourth quarter valued at $65,000. Alliancebernstein L.P. purchased a new stake in GoodRx during the third quarter valued at approximately $64,000. Virtu Financial LLC bought a new stake in shares of GoodRx during the 3rd quarter valued at $56,000. Shay Capital LLC purchased a new position in shares of GoodRx during the 3rd quarter valued at $47,000. Finally, Tower Research Capital LLC TRC grew its position in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after purchasing an additional 7,580 shares in the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.